Kinetic Trust (531274)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Book value of ₹11.88 per share provides some tangible asset backing.
• Latest quarter net profit is ₹0 Cr, so the company is not currently making losses.
• P/B of 1.45 is not an extreme valuation multiple, though it is not cheap.
• ROCE of 5.62% is higher than ROE, indicating operating assets generate a slightly better return than equity alone.

Concerns

• Zero sales growth and zero profit growth make the P/E of 33.62 unsupportable.
• ROE of 1.04% shows very little shareholder value creation.
• Piotroski F-score of 4/9, no dividend, and missing promoter/debt data make the financial health opaque and weak.
• Current price ₹17.27 is below the stated 52-week low of ₹25.47, reflecting severe market repricing.

AI Analysis

Let me start with what I look for: a business I can understand, durable economics, trustworthy management, and a price that leaves a margin of safety. Kinetic Trust is a microcap NBFC with a market cap of just ₹15 Cr, quarterly sales of ₹1 Cr and net profit of ₹0 Cr. That is not an earning machine; it is a financial entity barely breathing. Return on equity is 1.04% and ROCE is 5.62%—a lender earning barely 1% on shareholders' money has no pricing power and no moat. A moat must show up in returns; here it does not. The balance sheet offers some floor: book value is ₹11.88 per share, so the ₹17.27 price means I am paying 1.45 times book. That is not a bargain—it is a premium for a business with zero sales growth and zero profit growth. A P/E of 33.62 makes sense only if profits are about to take off, but the PEG of 0.03 is absurd when the stated growth rate is 0.00%. Perhaps that ratio uses a different earnings history; I cannot rely on it. The Piotroski F-score of 4/9 reinforces my caution—this is not a financially strengthening company. No dividend means I receive no compensation while I wait. Promoter holding is not disclosed, and debt-to-equity is not available; for an NBFC, saying nothing about leverage is not reassuring. The market tells a story: the price of ₹17.27 is below the stated 52-week range of ₹25.47–₹75.82. That kind of collapse usually reflects decaying fundamentals, not mere mispricing. You cannot value this with a growth model; it has no growth. You can only value it as an asset, but at 1.45 times book with 1% ROE, the assets themselves are not earning well. Graham would insist on a large discount to asset value. This has none. I will pass.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer